Discover how Chroma is expanding our impact.

Boston, MA, July 18, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Melissa J. Moore, Ph.D., to its Board of Directors. “Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines.” Currently serving as a Board Director and Scientific Advisory Board member for multiple biotechnology companies, Dr. Moore…

Boston, MA, June 27, 2024 – Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced it has entered into an exclusive license agreement with the Whitehead Institute to access intellectual property and technology developed in the lab of Chroma co-founder Jonathan Weissman, Ph.D.  The novel technology called CHARM (coupled histone tail for autoinhibition release of methyltransferase) uses a compact epigenetic editing effector domain to recruit and activate endogenous DNA methyltransferases to durably silence target genes. CHARM can utilize a self-silencing mechanism to limit its duration of expression and has been shown by Dr. Weissman’s lab to…

Boston, MA, May 20, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Jenny Marlowe, Ph.D., as the Company’s Chief Development Officer. Dr. Marlowe is a seasoned biopharma executive and scientific leader with deep expertise in translational, preclinical development, and preclinical safety across multiple genomic medicine modalities.  “I am thrilled to welcome Jenny to Chroma,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “Jenny joins our team at a pivotal time as we prepare to transition to the clinic. Her leadership, experience, and expertise will be instrumental as we work to bring…

Boston, December 10, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor (CAR) T cells at the American Society of Hematology (ASH) 65th Annual Meeting in San Diego. Allogeneic CAR T cell products offer advantages over autologous CAR T cells and have the potential to broaden access to cancer immunotherapy; however, their clinical effect remains limited by lack of durable response and challenges related to immunogenicity and graft-versus-host disease. Incorporating additional edits may help produce…